硫唑嘌呤长期治疗不缓解型多发性硬化症。
Prolonged azathioprine treatment of non-remitting multiple sclerosis.
作者信息
Rosen J A
出版信息
J Neurol Neurosurg Psychiatry. 1979 Apr;42(4):338-44. doi: 10.1136/jnnp.42.4.338.
Abstract
Two groups of 85 and 42 ambulatory patients with moderately advanced non-remitting multiple sclerosis were treated for six to 14 and three to six years with daily azathioprine. Less than 10% of these patients became confined to a wheelchair. This far exceeds any possible result in a group of non-remitting multiple sclerosis patients not so treated.
摘要
两组分别有85名和42名中度晚期非缓解型多发性硬化症门诊患者，接受了为期6至14年和3至6年的每日硫唑嘌呤治疗。这些患者中不到10% 的人需要依靠轮椅行动。这远远超过了一组未接受此类治疗的非缓解型多发性硬化症患者可能出现的任何结果。
相似文献
1
Prolonged azathioprine treatment of non-remitting multiple sclerosis.硫唑嘌呤长期治疗不缓解型多发性硬化症。
J Neurol Neurosurg Psychiatry. 1979 Apr;42(4):338-44. doi: 10.1136/jnnp.42.4.338.
2
Effectiveness of azathioprine treatment in multiple sclerosis.
Ital J Neurol Sci. 1988 Jun;9(3):261-4. doi: 10.1007/BF02334050.
3
The efficacy of azathioprine in relapsing-remitting multiple sclerosis.
Neurology. 1991 Jan;41(1):20-5. doi: 10.1212/wnl.41.1.20.
4
Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together.对硫唑嘌呤和β干扰素在所有类型多发性硬化症中的有效性进行间接荟萃分析比较。
J Neurol Sci. 2014 Dec 15;347(1-2):408-10. doi: 10.1016/j.jns.2014.10.029. Epub 2014 Oct 22.
5
Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness.硫唑嘌呤治疗多发性硬化症——一项关于其疗效的3年对照研究
J Neurol. 1980;223(2):97-117. doi: 10.1007/BF00313173.
6
Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group.参与硫唑嘌呤多中心试验的多发性硬化症患者的组织相容性抗原。英国和荷兰多发性硬化症硫唑嘌呤试验组。
J Neurol Neurosurg Psychiatry. 1988 Mar;51(3):412-5. doi: 10.1136/jnnp.51.3.412.
7
Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.硫唑嘌呤治疗多发性硬化症引发癌症的风险：一项病例对照研究。
Neurology. 1996 Jun;46(6):1607-12. doi: 10.1212/wnl.46.6.1607.
8
A double blind study on azathioprine efficacy in multiple sclerosis: final report.一项关于硫唑嘌呤治疗多发性硬化症疗效的双盲研究：最终报告。
J Neurol. 1993 May;240(5):295-8. doi: 10.1007/BF00838165.
9
Overview of azathioprine treatment in multiple sclerosis.
Lancet. 1991 Oct 26;338(8774):1051-5. doi: 10.1016/0140-6736(91)91909-e.
10
Long-term treatment of multiple sclerosis with azathioprine.硫唑嘌呤用于多发性硬化症的长期治疗。
J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):124-6. doi: 10.1136/jnnp.36.1.124.
引用本文的文献
1
Azathioprine for people with multiple sclerosis.硫唑嘌呤用于多发性硬化症患者。
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
2
Azathioprine. Safety profile in multiple sclerosis patients.硫唑嘌呤。多发性硬化症患者的安全性概况。
Neurol Sci. 2007 Dec;28(6):299-303. doi: 10.1007/s10072-007-0842-9.
3
Azathioprine for multiple sclerosis.硫唑嘌呤用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD003982. doi: 10.1002/14651858.CD003982.pub2.
4
A double blind study on azathioprine efficacy in multiple sclerosis: final report.一项关于硫唑嘌呤治疗多发性硬化症疗效的双盲研究：最终报告。
J Neurol. 1993 May;240(5):295-8. doi: 10.1007/BF00838165.
5
Immunological treatment of multiple sclerosis.多发性硬化症的免疫治疗
J Neurol. 1983;230(2):73-80. doi: 10.1007/BF00313634.
6
Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.
J Neurol. 1981;225(2):119-33. doi: 10.1007/BF00313325.
7
Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness.硫唑嘌呤治疗多发性硬化症——一项关于其疗效的3年对照研究
J Neurol. 1980;223(2):97-117. doi: 10.1007/BF00313173.
8
Effectiveness of azathioprine treatment in multiple sclerosis.
Ital J Neurol Sci. 1988 Jun;9(3):261-4. doi: 10.1007/BF02334050.
9
Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results.硫唑嘌呤治疗多发性硬化症疗效的双盲对照随机研究。初步结果。
Ital J Neurol Sci. 1988 Feb;9(1):53-7. doi: 10.1007/BF02334408.
10
Multiple sclerosis. Current concepts in management.多发性硬化症。管理方面的当前概念。
Drugs. 1985 Jan;29(1):88-95. doi: 10.2165/00003495-198529010-00004.
本文引用的文献
1
Survival in disseminated sclerosis: a clinical study of a series of cases first seen 20 years ago.播散性硬化症的生存率：对一系列20年前首次就诊病例的临床研究。
Brain. 1950;73(1):103-20. doi: 10.1093/brain/73.1.103.
2
Multiple sclerosis: prognosis for ambulatory and nonambulatory patients.
Res Publ Assoc Res Nerv Ment Dis. 1950;28:512-23.
3
Some aspects of the natural history of disseminated sclerosis.播散性硬化自然病史的某些方面。
Q J Med. 1952 Apr;21(82):135-67.
4
Course and prognosis of disseminated sclerosis in relation to age of onset.
AMA Arch Neurol Psychiatry. 1951 Nov;66(5):561-70.
5
Mortality and disability in multiple sclerosis; a statistical estimate of prognosis.多发性硬化症的死亡率和残疾情况；预后的统计估计
J Am Med Assoc. 1951 Aug 11;146(15):1367-9. doi: 10.1001/jama.1951.03670150001001.
6
Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine.实验性变应性脑脊髓炎：6-巯基嘌呤的作用
J Exp Med. 1962 Sep 1;116(3):311-27. doi: 10.1084/jem.116.3.311.
7
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.多发性硬化症治疗的实验性试验问题：多发性硬化症治疗实验性试验评估小组报告
Ann N Y Acad Sci. 1965 Mar 31;122:552-68. doi: 10.1111/j.1749-6632.1965.tb20235.x.
8
PROGNOSTIC CRITERIA IN MULTIPLE SCLEROSIS.多发性硬化症的预后标准。
Ann N Y Acad Sci. 1965 Mar 31;122:542-51. doi: 10.1111/j.1749-6632.1965.tb20234.x.
9
CLINICAL STUDIES OF MULTIPLE SCLEROSIS IN ISRAEL. 3. CLINICAL COURSE AND PROGNOSIS RELATED TO AGE AT ONSET.以色列多发性硬化症的临床研究。3. 与发病年龄相关的临床病程及预后。
Neurology. 1964 Oct;14:926-32. doi: 10.1212/wnl.14.10.926.
10
The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease.多发性硬化症的良性型。一项基于发病三年内确诊的241例病例，并随访至疾病第十年或更久的研究。
Brain. 1961 Jun;84:186-203. doi: 10.1093/brain/84.2.186.
Zotero 插件